Your browser doesn't support javascript.
loading
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Buzdar, Aman U; Ibrahim, Nuhad K; Francis, Deborah; Booser, Daniel J; Thomas, Eva S; Theriault, Richard L; Pusztai, Lajos; Green, Marjorie C; Arun, Banu K; Giordano, Sharon H; Cristofanilli, Massimo; Frye, Debra K; Smith, Terry L; Hunt, Kelly K; Singletary, Sonja E; Sahin, Aysegul A; Ewer, Michael S; Buchholz, Thomas A; Berry, Donald; Hortobagyi, Gabriel N.
Afiliação
  • Buzdar AU; Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA. abuzdar@mdanderson.org
J Clin Oncol ; 23(16): 3676-85, 2005 Jun 01.
Article em En | MEDLINE | ID: mdl-15738535
Assuntos
Buscar no Google
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Terapia Neoadjuvante Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2005 Tipo de documento: Article
Buscar no Google
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Terapia Neoadjuvante Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2005 Tipo de documento: Article